Thomas J. Anchordoquy

University of Colorado Anschutz Medical Campus

Biochemistry, Genetics and Molecular BiologyMaterials Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions”.

Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions

ACS Nano(2024)10.1021/acsnano.4c00182

N/A

0.668DataRank · unranked

85 citations

Natalie Artzi, Irina V. Balyasnikova, Yechezkel Barenholz, Ninh M. La‐Beck, Jacob S. Brenner +23 more

Role of Serum Stability and Lipoprotein Interactions in Lipid Structure–Tumor Accumulation Relationship

ACS Nano(2025)10.1021/acsnano.5c10594

N/A

0.104DataRank · unranked

1 citations

Hanmant Gaikwad, David J. Siegel, David Angarita, Morgan Nebbia, Thomas J. Anchordoquy +9 more

The Use of Lactose as an Alternative Coating for Nanoparticles

Journal of Pharmaceutical Sciences(2020)10.1016/j.xphs.2020.01.019

N/A

0DataRank · unranked

16 citations

Thomas J. Anchordoquy, Jamie L. Betker

Reducing off-target drug accumulation by exploiting a type-III interferon response

Journal of Controlled Release(2023)10.1016/j.jconrel.2023.05.029

N/A

0DataRank · unranked

12 citations

Madison H Ricco, Emily A. Hemann, Thomas J. Anchordoquy, Scott Tilden

Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy

European Journal of Pharmaceutical Sciences(2024)10.1016/j.ejps.2024.106974

N/A

0DataRank · unranked

2 citations

Madison H Ricco, Emily A. Hemann, Thomas J. Anchordoquy, Scott Tilden